Drug intelligence / Profile preview

lactobacillus plantarum DSM 15312 + lactobacillus paracasei DSM 13434

Development stage: Unknown
Lead developer: Probi
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This is a **combination of two probiotic bacterial strains**—Lactobacillus plantarum DSM 15312 and Lactobacillus paracasei DSM 13434—both of which are lactic acid bacteria with well-characterized immunomodulatory effects. The combination has been studied for its ability to modulate immune responses, most notably by increasing regulatory T cell (Treg) frequency and anti-inflammatory cytokines (IL-10, TGF-β), and by reducing pro-inflammatory cytokines such as IFN-γ and IL-17. Clinical and preclinical studies have evaluated this probiotic mix for the management of autoimmune conditions such as multiple sclerosis and for prevention/treatment of respiratory tract infections (e.g., the common cold). Its proposed mechanism is oral modulation of gut-immune interactions via cytokine induction and regulatory cell promotion, leading to systemic anti-inflammatory and immunoregulatory effects[1][2][5][7].

Brand names: Probi Defendum
Other names: lactobacillus plantarum HEAL 9 + lactobacillus paracasei 8700:2

Beyond the preview

Go deeper on lactobacillus plantarum DSM 15312 + lactobacillus paracasei DSM 13434.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus plantarum DSM 15312 + lactobacillus paracasei DSM 13434.

Explore the full profile